Skip to main content

Advertisement

SpringerLink
Log in

Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The optimal treatment strategy for elderly patients with natural killer/T-cell lymphoma (NKTCL) remains to be established. A total of 63 elderly patients with newly diagnosed NKTCL were retrospectively reviewed. Among the patients with stage I–II disease, 58.3 % received radiotherapy (RT) ± chemotherapy, and 41.7 % received chemotherapy alone. Compared with chemotherapy alone, RT ± chemotherapy elicited a significantly higher overall response rate (ORR) (100 vs. 57.1 %, P < 0.001) and substantially prolonged 5-year overall survival (OS) (55.3 vs. 18.0 %, P < 0.001) in patients with stage I–II disease. Compared with other chemotherapeutic regimens, pegaspargase plus gemcitabine and oxaliplatin (PGEMOX)/L-asparaginase plus gemcitabine and oxaliplatin (GELOX) was associated with a significantly higher ORR (92.9 vs. 51.6 %, P = 0.009) and a significantly improved 5-year OS (78.6 vs. 23.9 %, P = 0.010) in patients with stage I–II disease. Nine patients with stage I–II disease who were treated with PGEMOX/GELOX followed by RT had an encouraging outcome (5-year OS 100 %, 5-year progression-free survival (PFS) 85.7 %), which was superior to that of patients receiving other regimens followed by RT. In conclusion, RT played an important role for elderly patients with early-stage NKTCL, and the PGEMOX/GELOX regimen was superior to other regimens. The combination of them may be a promising treatment option.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103(1):216–221. doi:10.1182/blood-2003-05-1401

    Article  CAS  PubMed  Google Scholar 

  2. Vose J, Armitage J, Weisenburger D (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130. doi:10.1200/JCO.2008.16.4558

    Article  PubMed  Google Scholar 

  3. Chan JK, Jaffe ES, Ralfkiaer E (2001) Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 3rd edn. IARC, Lyon, pp 204–207

    Google Scholar 

  4. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C (2008) Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 285–288

    Google Scholar 

  5. Li YX, Wang H, Jin J, Wang WH, Liu QF, Song YW, Wang ZY, Qi SN, Wang SL, Liu YP, Liu XF, Yu ZH (2012) Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma. Int J Radiat Oncol Biol Phys 82(5):1809–1815. doi:10.1016/j.ijrobp.2010.10.040

    Article  PubMed  Google Scholar 

  6. Bi XW, Li YX, Fang H, Jin J, Wang WH, Wang SL, Liu YP, Song YW, Ren H, Dai JR (2013) High-dose and extended-field intensity modulated radiation therapy for early-stage NK/T-cell lymphoma of Waldeyer’s ring: dosimetric analysis and clinical outcome. Int J Radiat Oncol Biol Phys 87(5):1086–1093. doi:10.1016/j.ijrobp.2013.08.040

    Article  PubMed  Google Scholar 

  7. Wang B, Li XQ, Ma X, Hong X, Lu H, Guo Y (2008) Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol 83(10):795–799. doi:10.1002/ajh.21256

    Article  PubMed  Google Scholar 

  8. Kim BS, Kim DW, Im SA, Kim CW, Kim TY, Yoon SS, Heo DS, Bang YJ, Park S, Kim BK, Kim NK (2009) Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol 20(1):121–128. doi:10.1093/annonc/mdn551

    Article  PubMed  Google Scholar 

  9. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ (2012) Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol 96(5):617–623. doi:10.1007/s12185-012-1174-y

    Article  CAS  PubMed  Google Scholar 

  10. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O (2011) Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood 117(6):1834–1839. doi:10.1182/blood-2010-09-307454

    Article  CAS  PubMed  Google Scholar 

  11. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R (2011) Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 29(33):4410–4416. doi:10.1200/JCO.2011.35.6287

    Article  CAS  PubMed  Google Scholar 

  12. Kwong YL, Kim WS, Lim ST, Kim SJ, Tang T, Tse E, Leung AY, Chim CS (2012) SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood 120(15):2973–2980. doi:10.1182/blood-2012-05-431460

    Article  CAS  PubMed  Google Scholar 

  13. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung C, Park K, Kim WS (2006) Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24(4):612–618. doi:10.1200/JCO.2005.04.1384

    Article  PubMed  Google Scholar 

  14. Jo JC, Yoon DH, Kim S, Lee BJ, Jang YJ, Park CS, Huh J, Lee SW, Ryu JS, Suh C (2012) Clinical features and prognostic model for extranasal NK/T-cell lymphoma. Eur J Haematol 89(2):103–110. doi:10.1111/j.1600-0609.2012.01796.x

    Article  PubMed  Google Scholar 

  15. Li S, Feng X, Li T, Zhang S, Zuo Z, Lin P, Konoplev S, Bueso-Ramos CE, Vega F, Medeiros LJ, Yin CC (2013) Extranodal NK/T-cell lymphoma, nasal type: a report of 73 cases at MD Anderson Cancer Center. Am J Surg Pathol 37(1):14–23. doi:10.1097/PAS.0b013e31826731b5

    Article  CAS  PubMed  Google Scholar 

  16. Kim TM, Lee SY, Jeon YK, Ryoo BY, Cho GJ, Hong YS, Kim HJ, Kim SY, Kim CS, Kim S, Kim JS, Sohn SK, Song HH, Lee JL, Kang YK, Yim CY, Lee WS, Yuh YJ, Kim CW, Heo DS (2008) Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 19(8):1477–1484. doi:10.1093/annonc/mdn147

    Article  CAS  PubMed  Google Scholar 

  17. Shipp MA, Anderson JR, Armitage JO, Bonadonna G, Brittinger G, Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister TA, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yead BY (1993) A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329(14):987–994. doi:10.1056/NEJM199309303291402

    Article  Google Scholar 

  18. Wang ZY, Li YX, Wang H, Wang WH, Jin J, Liu YP, Song YW, Wang SL, Liu XF, Yu ZH (2011) Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma. Ann Oncol 22(2):390–396. doi:10.1093/annonc/mdq347

    Article  CAS  PubMed  Google Scholar 

  19. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244–1253

    CAS  PubMed  Google Scholar 

  20. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586. doi:10.1200/JCO.2006.09.2403

    Article  PubMed  Google Scholar 

  21. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, Wang SL, Liu XF, Zhou LQ, He XH, Lu N, Yu ZH (2006) Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24(1):181–189. doi:10.1200/JCO.2005.03.2573

    Article  PubMed  Google Scholar 

  22. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, Okada J, Itami J, Ito H (2006) Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 106(3):609–615. doi:10.1002/cncr.21656

    Article  PubMed  Google Scholar 

  23. Huang MJ, Jiang Y, Liu WP, Li ZP, Li M, Zhou L, Xu Y, Yu CH, Li Q, Peng F, Liu JY, Luo F, Lu Y (2008) Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 70(1):166–174. doi:10.1016/j.ijrobp.2007.05.073

    Article  PubMed  Google Scholar 

  24. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, Xia YF, Xia ZJ (2013) First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer 119(2):348–355. doi:10.1002/cncr.27752

    Article  CAS  PubMed  Google Scholar 

  25. Kim GE, Lee SW, Chang SK, Park HC, Pyo HR, Kim JH, Moon SR, Lee HS, Choi EC, Kim KM (2001) Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 61(3):261–269. doi:10.1016/S0167-8140(01)00428-5

    Article  CAS  PubMed  Google Scholar 

  26. Kim K, Chie EK, Kim CW, Kim IH, Park CI (2005) Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 35(1):1–5. doi:10.1093/jjco/hyi006

    Article  CAS  PubMed  Google Scholar 

  27. Ma HH, Qian LT, Pan HF, Yang L, Zhang HY, Wang ZH, Ma J, Zhao YF, Gao J, Wu AD (2010) Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol 27(3):798–806. doi:10.1007/s12032-009-9288-7

    Article  PubMed  Google Scholar 

  28. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, Vose J, Armitage JO, Liang R (2009) Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113(17):3931–3937. doi:10.1182/blood-2008-10-185256

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81071950, 81301903).

Conflict of interest

The authors declare that they have no conflict of interest.

Compliance with ethical standards

This is a retrospective study, and all patients provided informed consent for the collection of medical information at their first medical visit. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, People’s Republic of China

    Xi-wen Bi, Yi Xia, Peng Sun, Pan-pan Liu, Yu Wang, Jia-jia Huang, Wen-qi Jiang & Zhi-ming Li

  2. Department of Radiation Oncology, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, People’s Republic of China

    Wen-wen Zhang

  3. State Key Laboratory of Oncology in South China, Guangzhou, 510060, People’s Republic of China

    Xi-wen Bi, Yi Xia, Wen-wen Zhang, Peng Sun, Pan-pan Liu, Yu Wang, Jia-jia Huang, Wen-qi Jiang & Zhi-ming Li

  4. Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People’s Republic of China

    Xi-wen Bi, Yi Xia, Wen-wen Zhang, Peng Sun, Pan-pan Liu, Yu Wang, Jia-jia Huang, Wen-qi Jiang & Zhi-ming Li

Authors
  1. Xi-wen Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-wen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pan-pan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jia-jia Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wen-qi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Zhi-ming Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhi-ming Li.

Additional information

Xi-wen Bi and Yi Xia contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bi, Xw., Xia, Y., Zhang, Ww. et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol 94, 1525–1533 (2015). https://doi.org/10.1007/s00277-015-2395-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2395-y

Keywords

Search

Navigation